☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Progressive Phenotype
Boehringer Ingelheim's Ofev (nintedanib) as the First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype
March 10, 2020
Boehringer Ingelheim's Ofev (nintedanib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a...
October 11, 2019
Load more...
Back to Home